IMV Inc IMVIF

RE:New appointment to the Board of Directors

[qwerty22]

Seems clear what IMV are signalling here. I tend to think they don't signal without some substance.

Breakthorough wrote: Prior to joining Goldfinch Bio, Mr. Kuvalanka advised private biopharmaceutical and portfolio companies of venture capital firms, including Third Rock Ventures, on their corporate and financial strategies and helped to build several investor syndicates. Previously, he served as Chief Operating Officer and Principal Financial and Accounting Officer at Syros Pharmaceuticals (Nasdaq: SYRS) and Chief Business Officer and Principal Financial and Accounting Officer at Blueprint Medicines (Nasdaq: BPMC). In these roles, Mr. Kuvalanka helped to transition the companies from early-stage start-ups to publicly traded, clinical-stage organizations. In particular, he built the business and finance functions, led the execution of several financings, including the companies initial public offerings, and led the negotiations of the companies early strategic collaborations. Earlier in his career, Mr. Kuvalanka worked in roles of increasing responsibility over twelve years at Millennium: The Takeda Oncology Company, including as Vice President of Business Development and Corporate Strategy and a member of the companys executive leadership team. He holds an MBA from the Wharton School of the University of Pennsylvania, and a BA with Honors from Wesleyan University. https://www.businesswire.com/news/home/20210325005250/en/